

FOR IMMEDIATE RELEASE

11th September 2019

Glycostem enters into strategic Asian collaboration

11th September 2019, Oss, the Netherlands — Glycostem Therapeutics BV, a clinical stage and leading NK-cell company, today announced the signing of a two agreements with an undisclosed Korean pharmaceutical company. The objective of both agreements is treatment of hard-to-treat cancers through the use of non-manipulated and genetically manipulated Natural Killer cells (NK-cells).

The collaboration will focus on two activities:

1. An exclusive commercialisation agreement for oNKord® (non-manipulated NK-cells and Glycostem's lead product) for Korea and Japan against down and milestone payments; and
2. A co-development agreement for a CAR-NK product (genetically manipulated NK-cells, target not disclosed) for which the undisclosed Korean pharmaceutical company has global commercialisation rights.

Glycostem's brings its extensive expertise and experience with NK-cells and their state-of-the-art GMP licensed production facility into this collaboration.

Troels Jordansen, CEO of Glycostem said "We have spent quite some time in Asia and it is generally accepted that they are pioneers in the field of cellular immunotherapy. That's why we are very excited to be working closely with our Korean partners to make available safe, cost



Contact:

Troels Jordansen +31 6 1834 5326 - Troels@Glycostem.com – www.Glycostem.com

effective and highly potent cellular immunotherapy products for patients in Asia and across the world.”

- end -

About Glycostem

Netherlands-based Glycostem Therapeutics BV, a clinical stage biotech company, develops allogeneic cellular immunotherapy to treat several types of cancer. By harnessing the power of stem cell-derived Natural Killer (NK) cells, Glycostem’s products are a safer alternative to CAR-T-cells as there are no Graft versus Host Disease. Glycostem’s lead product, oNKord[®], is manufactured from allogeneic raw material and is available off-the shelf.

oNKord[®] is produced in a closed system in Glycostem’s state-of-the-art and GMP (Good Manufacturing Process) licensed production facility in the Netherlands, from which it can be distributed globally. The production technology includes *ex vivo* generation of high numbers of NK-cells with a high degree of purity for clinical applications. oNKord[®] successfully passed phase I clinical trial (elderly and frail AML - Acute Myeloid Leukemia - patients), providing solid safety data and strong indication of clinical activity, including response on MRD (Minimal Residual Disease). Results indicate that oNKord[®] may be safely infused in patients with AML patients.

Glycostem is furthermore developing a range of CAR-NK products in-house and in cooperation with global partners including MolMed SPA (BIT:MLM).

Thanks to its eight patent families, longstanding technical expertise and resources, as well as ‘Orphan Drug Designation’, Glycostem has secured a leadership position in the global NK-cell market.



Contact:

Troels Jordansen +31 6 1834 5326 - Troels@Glycostem.com - www.Glycostem.com